RxDoctor Payments Data

Sandeep Gulati, DO

Neurology · Bronx, NYNPI 1740292051

Payments from drug & device makers

$156,253in general payments, 2019–2025

Across 2,118 payments — averaging $73.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$60K
  • AbbVie$54K
  • Otsuka America Pharmaceutical, Inc.$8K
  • Axsome Therapeutics, Inc.$6K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Amneal Pharmaceuticals LLC$2K
  • plus $24K from 54 others

What the payments were for

  • Consulting fees$1,9501%
  • Speaking & faculty fees$110,40071%
  • Travel & lodging$2,4622%
  • Food & beverage$41,37226%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.144$60,007
AbbVie(2 entities)456$54,121
Otsuka America Pharmaceutical, Inc.85$8,336
Axsome Therapeutics, Inc.12$5,684
Teva Pharmaceuticals USA, Inc.123$2,121
Amneal Pharmaceuticals LLC102$1,911
Novartis111$1,851
Biogen78$1,705
Lundbeck LLC78$1,579
Pfizer55$1,184
AstraZeneca(2 entities)46$1,132
SK Life Science, Inc.60$1,101
Lilly USA, LLC67$1,068
Bristol Myers Squibb84$1,056
MDD US Operations, LLC39$1,023
Amgen(2 entities)41$859
Kyowa Kirin, Inc.38$798
UCB, Inc.39$776
Avanir Pharmaceuticals, Inc.32$740
Neurocrine Biosciences, Inc.27$675
Adamas Pharmaceuticals, Inc.38$625
Johnson & Johnson(2 entities)19$486
Neurelis, Inc.16$485
Genentech USA, Inc.18$458
Sunovion Pharmaceuticals Inc.23$443
Grifols USA, LLC21$399
Argenx US, Inc.16$376
Biohaven Pharmaceuticals, Inc.22$340
Alnylam Pharmaceuticals Inc.16$335
Biohaven Pharmaceutical Holding Company Ltd.16$326
Abbott12$319
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)12$295
GE HealthCare11$268
Eisai Inc.10$222
Acadia Pharmaceuticals Inc12$191
Takeda Pharmaceuticals U.S.A., Inc.7$190
Mallinckrodt Enterprises LLC6$184
Supernus Pharmaceuticals, Inc.6$176
CSL Behring7$175
Idorsia Pharmaceuticals US Inc7$138
Currax Pharmaceuticals LLC12$137
Sanofi6$137
Medtronic(2 entities)3$132
Vanda Pharmaceuticals Inc.8$132
Acorda Therapeutics, Inc6$108
Alfasigma USA, Inc.7$104
Sumitomo Pharma America, Inc.6$100
Scilex Pharmaceuticals Inc.7$98
Avion Pharmaceuticals5$93
TG Therapeutics, Inc.4$90
Corium, LLC4$86
E.r. Squibb & Sons, L.L.C.4$84
Boston Scientific2$77
Life Molecular Imaging Ltd2$74
Almatica Pharma LLC3$59
Catalyst Pharmaceuticals, Inc.3$56
Baxter Healthcare1$55
Akcea Therapeutics, Inc.3$44
Xeris Pharmaceuticals, Inc.2$40
Averitas Pharma Inc.1$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$156,253 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$249,059
Medicare patients
491
Services billed
7,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina168$208,777
VumerityDiroximel Fumarate12$149,414
UbrelvyUbrogepant108$139,201
RexultiBrexpiprazole67$104,413
RytaryCarbidopa/Levodopa68$54,389
Nurtec OdtRimegepant Sulfate29$44,758
QuliptaAtogepant40$43,503
Emgality PenGalcanezumab-Gnlm57$39,755
NourianzIstradefylline19$36,852
Ajovy AutoinjectorFremanezumab-Vfrm40$27,500
Aimovig AutoinjectorErenumab-Aooe31$25,118
Lacosamide48$8,001
AdlarityDonepezil Hcl17$7,346
Memantine Hcl509$6,071
Levetiracetam121$3,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$54,121$391,481316 claims
BiogenVumerity$1,705$149,41412 claims
Otsuka America Pharmaceutical, Inc.Rexulti$8,336$104,41367 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$1,911$54,98982 claims
PfizerNurtec Odt$1,184$44,75829 claims
Kyowa Kirin, Inc.Nourianz$798$36,85219 claims
Corium, LLCAdlarity$86$7,34617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →